Literature DB >> 18213529

Immunoglobulin constant heavy G subclass chain genes in asthma and allergy.

Vivi-Anne Oxelius1.   

Abstract

The IGHG (ImmunoGlobulin constant Heavy G chain) genes are situated close to the IGHE gene on chromosome 14q32, 5'mu, delta, gamma3, gamma1, alpha1, gamma2, gamma4, epsilon, alpha2, 3', in linkage disequilibrium. The polymorphism of gamma3, gamma1 and gamma2 genes, is investigated as alternative allotypes. They are inherited in a Mendelian fashion and are expressed randomly in allelic exclusion. The alternative and functionally different gamma3, gamma1 and gamma2 gene variants, are found in four IGHG haplotypes, coding 4 B-cell variants: IGHG*bfn (=B1-cells), IGHG*bf-n (=B2-cells), IGHG*gan (=B3-cells) and IGHG*ga-n (=B4-cells). The dominance of the IGHG2*n allele from the IGHG*bfn haplotype (=B1-cells) has been shown in repeated investigations, namely in patients with asthma and allergy with increased serum levels of IgE > 600 ku/l and more often so in those with IgE > 1,000 ku/l or IgG4>1 g/l, in childhood asthma patients with mean level of IgE = 1,762 ku/l and in allergen exposed individuals developing laboratory animal allergy. In children with non-atopy and mean IgE level = 9.5 ku/l there is instead a dominance of the alternative allotypes from the IGHG*ga-n (=B4-cells) with IGHG2*-n alleles. In a case-control study allergic children with a family history of allergy, clinically manifest allergy and/or positive SPT, the IGHG*bfn haplotype (=B1-cells) with the IGHG2*n allele dominates, with increased risk of atopy and the IGHG*bf-n haplotype (=B2-cells) with the IGHG2*-n allele is infrequent with low risk, probably protective against atopy. The phenotypic expressions of the IGHG*bfn haplotype (=B1 cells) and IGHG*bfn/*bfn diplotypes (B1/B1-cells) are increased IgG2*n allotype together with increased IgE serum levels and IgE sensitisation in agreement with atopy. The alternative IGHG*ga-n/*ga-n diplotype (B4/B4-cells) express low IgG1*a- and IgG2*-n allotypes, together with low IgE and non-IgE sensitisation, in agreement with non-atopy. Together these studies have given us a greater understanding of the involvement of IGHG genes, IGHG coded B-cells and immunochemical and functional variants of IgG molecules describing different forms of asthma and allergy, which will improve diagnoses and treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18213529     DOI: 10.1007/s12026-007-0007-1

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  33 in total

1.  Serum Gm allotype development during childhood.

Authors:  V A Oxelius; M Aurivillius; A M Carlsson; K Musil
Journal:  Scand J Immunol       Date:  1999-10       Impact factor: 3.487

2.  Preparation of IgG subclass allotypes from polyclonal IgG.

Authors:  V A Oxelius
Journal:  Scand J Immunol       Date:  1999-04       Impact factor: 3.487

3.  Immunoglobulin constant heavy G chain genes as risk factors in childhood allergies.

Authors:  V-A Oxelius; L Bråbäck; S Ahlstedt; B Björkstén
Journal:  Clin Exp Allergy       Date:  2006-12       Impact factor: 5.018

4.  Serum IgG and IgG subclass contents in different Gm phenotypes.

Authors:  V A Oxelius
Journal:  Scand J Immunol       Date:  1993-02       Impact factor: 3.487

5.  Alternative G1m, G2m and G3m allotypes of IGHG genes correlate with atopic and nonatopic pathways of immune regulation in children with bronchial asthma.

Authors:  V A Oxelius; A M Carlsson; M Aurivillius
Journal:  Int Arch Allergy Immunol       Date:  1998-03       Impact factor: 2.749

6.  Different Gm allotype amounts in human intravenous immunoglobulin (IVIG) preparations; survival of foreign Gm allotypes in immunodeficient patients.

Authors:  V A Oxelius; M M Eibl
Journal:  Clin Exp Immunol       Date:  1996-11       Impact factor: 4.330

Review 7.  Genetics and genomics of asthma and allergic diseases.

Authors:  William Cookson
Journal:  Immunol Rev       Date:  2002-12       Impact factor: 12.988

8.  Association between immunoglobulin allotypes and immune responses to Haemophilus influenzae and Meningococcus polysaccharides.

Authors:  J P Pandey; H H Fudenberg; G Virella; C U Kyong; C B Loadholt; R M Galbraith; E C Gotschlich; J C Parke
Journal:  Lancet       Date:  1979-01-27       Impact factor: 79.321

9.  Fc epsilon RI-beta polymorphism and risk of atopy in a general population sample.

Authors:  M R Hill; A L James; J A Faux; G Ryan; J M Hopkin; P le Söuef; A W Musk; W O Cookson
Journal:  BMJ       Date:  1995-09-23

10.  IgG3 deficiency: common in obstructive lung disease. Hereditary in families with immunodeficiency and autoimmune disease.

Authors:  V A Oxelius; L A Hanson; J Björkander; L Hammarström; A Sjöholm
Journal:  Monogr Allergy       Date:  1986
View more
  6 in total

1.  Functional expression of IgG-Fc receptors in human airway smooth muscle cells.

Authors:  YuXiu C Xia; Michael Schuliga; Malcolm Shepherd; Maree Powell; Trudi Harris; Shenna Y Langenbach; Peck Szee Tan; William T Gerthoffer; P Mark Hogarth; Alastair G Stewart; Graham A Mackay
Journal:  Am J Respir Cell Mol Biol       Date:  2010-07-01       Impact factor: 6.914

Review 2.  Human immunoglobulin allotypes: possible implications for immunogenicity.

Authors:  Roy Jefferis; Marie-Paule Lefranc
Journal:  MAbs       Date:  2009 Jul-Aug       Impact factor: 5.857

3.  IgG4-related Inflammatory Abdominal Aortic Aneurysm, Spectrum of IgG4-related Chronic Periaortitis.

Authors:  Satomi Kasashima; Yoh Zen
Journal:  Ann Vasc Dis       Date:  2010-12-02

Review 4.  Mendelian and trans-generational inheritance in hypertensive renal disease.

Authors:  Michael C Braun; Peter A Doris
Journal:  Ann Med       Date:  2012-06       Impact factor: 4.709

Review 5.  Genetic susceptibility to hypertensive renal disease.

Authors:  Peter A Doris
Journal:  Cell Mol Life Sci       Date:  2012-05-05       Impact factor: 9.261

6.  FcγR Binding and ADCC Activity of Human IgG Allotypes.

Authors:  Steven W de Taeye; Arthur E H Bentlage; Mirjam M Mebius; Joyce I Meesters; Suzanne Lissenberg-Thunnissen; David Falck; Thomas Sénard; Nima Salehi; Manfred Wuhrer; Janine Schuurman; Aran F Labrijn; Theo Rispens; Gestur Vidarsson
Journal:  Front Immunol       Date:  2020-05-06       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.